Latest news
How Investors Are Reacting To Replimune Group (REPL) FDA Accelerated Approval For New Melanoma Therapy - simplywall.stsimplywall.st · Mon, 10 Aug 2026 18:59:38 GMTThe week in pharma: action, reaction and insight – week to August 7, 2026 - The Pharma LetterThe Pharma Letter · Sun, 09 Aug 2026 12:51:30 GMTFDA Approves Replimune's Tudriqev for Advanced Melanoma After Two Previous Rejections - Medical DailyMedical Daily · Sat, 08 Aug 2026 14:30:41 GMTFDA Grants Accelerated Approval to Replimune's Tudriqev Plus Nivolumab for Advanced Melanoma - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 17:19:39 GMTTudriqev: US FDA Approves Replimune's Skin Cancer Drug After Rejecting It Twice - Health and MeHealth and Me · Fri, 07 Aug 2026 12:34:03 GMTIt’s Official: US FDA Approves Replimune’s Melanoma Drug - The Dermatology DigestThe Dermatology Digest · Thu, 06 Aug 2026 21:37:13 GMTReplimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:13:55 GMTReplimune's Rollercoaster: From Double Rejection to FDA Panel Endorsement - AD HOC NEWSAD HOC NEWS · Tue, 04 Aug 2026 04:23:08 GMT